The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2016

Filed:

Mar. 12, 2012
Applicants:

Martin E. Gleave, Vancouver, CA;

Amina Zoubeidi, West Vancouver, CA;

François Lamoureux, Breze, FR;

Inventors:

Martin E. Gleave, Vancouver, CA;

Amina Zoubeidi, West Vancouver, CA;

François Lamoureux, Breze, FR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61K 31/713 (2006.01); A61K 31/4162 (2006.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); A61K 31/416 (2006.01); C07H 21/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/416 (2013.01); A61K 31/4162 (2013.01); A61K 31/7088 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention provides a method for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Heat Shock Protein 90 (Hsp90) inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject. The present invention also provides pharmaceutical compositions comprising an amount of an oligonucleotide which reduces clusterin expression, and a Hsp90 inhibitor for use in treating a mammalian subject affected by prostate cancer. Also provided are oligonucleotides which reduce clusterin expression for use in combination with a Hsp90 inhibitor in treating a mammalian subject affected by prostate cancer, and a composition for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Hsp90 inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject.


Find Patent Forward Citations

Loading…